The estimated Net Worth of John C. Jr Davis is at least $927 Tysiąc dollars as of 2 January 2020. John Davis owns over 11,294 units of Magenta Therapeutics Inc stock worth over $13,719 and over the last 6 years he sold MGTA stock worth over $0. In addition, he makes $913,521 as Chief Medical Officer i Head of Research and Development at Magenta Therapeutics Inc.
John has made over 3 trades of the Magenta Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 11,294 units of MGTA stock worth $107,180 on 2 January 2020.
The largest trade he's ever made was exercising 21,669 units of Magenta Therapeutics Inc stock on 9 December 2019 worth over $205,639. On average, John trades about 4,235 units every 3 days since 2018. As of 2 January 2020 he still owns at least 19,598 units of Magenta Therapeutics Inc stock.
You can see the complete history of John Davis stock trades at the bottom of the page.
Dr. John C. Davis M.D. serves as Chief Medical Officer, Head of Research and Development of the Company. Prior to joining Magenta, Dr. Davis was Senior Vice President and Head of Early Clinical Development at Pfizer Inc. from 2016 to 2018. Prior to his role at Pfizer, Dr. Davis served as Vice President and Global Therapeutic Area Head of Immunology at Baxalta which is now wholly-owned by Shire plc, from 2015 to 2016. Dr. Davis had multiple roles at Genentech, Inc. from 2007 to 2015 and ultimately was Senior Group Director and Head of the Inflammation and Cardiovascular/Metabolism Group in the Early Clinical Development Group. Dr. Davis spent nearly 10 years on faculty at The University of California San Francisco leading clinical research in autoimmune diseases, where he most recently was Professor of Clinical Medicine until 2015. He continues to see patients, teach, and serve as volunteer faculty at the Boston VA Medical Center. Dr. Davis earned an M.D. from the University of Maryland. Dr. Davis trained in Internal Medicine and Rheumatology at The University of California San Francisco. He continued training in clinical research and rheumatology at The National Institutes of Health NIAMS Intramural Program.
As the Chief Medical Officer i Head of Research and Development of Magenta Therapeutics Inc, the total compensation of John Davis at Magenta Therapeutics Inc is $913,521. There are 2 executives at Magenta Therapeutics Inc getting paid more, with Christina Isacson having the highest compensation of $2,277,560.
John Davis is 58, he's been the Chief Medical Officer i Head of Research and Development of Magenta Therapeutics Inc since 2020. There are 5 older and 15 younger executives at Magenta Therapeutics Inc. The oldest executive at Magenta Therapeutics Inc is David Scadden, 67, who is the Independent Director.
John's mailing address filed with the SEC is C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at Magenta Therapeutics Inc have traded over $6,775,591 worth of Magenta Therapeutics Inc stock and bought 1,257,000 units worth $10,105,000 . The most active insiders traders include Bruce Booth, Rock Ventures Iv, L.P.Third... oraz Jeffrey W. Albers. On average, Magenta Therapeutics Inc executives and independent directors trade stock every 46 days with the average trade being worth of $99,614. The most recent stock trade was executed by Rock Ventures Iv, L.P.Third... on 7 February 2023, trading 3,700,000 units of MGTA stock currently worth $3,071,000.
magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.
Magenta Therapeutics Inc executives and other stock owners filed with the SEC include: